Russian Venture Company (RVC) Biofund, a Russian-based investment firm, and Quintiles, the world’s leading biopharmaceutical services company, have agreed to expand the development of clinical services in Russia. Specifically, both partners will work to address Russia’s healthcare initiatives in accordance with its Healthcare 2020 Development Program. To meet these objectives, they plan to set up specific joint ventures in the near future.
Commenting on the agreement, RVC CEO Igor Agamirzian noted that RVC Biofund was established with the purpose of investing into biopharmaceutical companies and biotech start-ups, while RVC Biofund CEO Egor Beketov hopes the partnership with Quintiles will help create high-technology companies in Russia to advance biopharma. From his side, Quintiles Russia Clinical Services General Manager Sergei Borisov said the partnership with RVC supports Quintiles’ growth initiatives within Russia, and aligns its New Health focus with the country’s 2020 Healthcare Program.
Web design,